Intersect ENT, Inc
XENT
XENT was delisted on the 12th of May, 2022.
138 hedge funds and large institutions have $808M invested in Intersect ENT, Inc in 2018 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 50 increasing their positions, 42 reducing their positions, and 43 closing their positions.
41% more call options, than puts
Call options by funds: $24.2M | Put options by funds: $17.2M
19% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 42
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less funds holding
Funds holding: 160 → 138 (-22)
22% less capital invested
Capital invested by funds: $1.03B → $808M (-$227M)
51% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$33.9M |
| 2 |
Millennium Management
New York
|
+$27.8M |
| 3 |
HM
HealthCor Management
New York
|
+$20.5M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.64M |
| 5 |
BlackRock
New York
|
+$8.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$38.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$29.3M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$16.3M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$14.2M |
| 5 |
Renaissance Technologies
New York
|
-$10.9M |
XENT Hedge Fund Activity: Q3 2018 in Review
138 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Intersect ENT, Inc (XENT) for Q3 2018, worth a combined $808M — down 22% from $1.03B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of XENT and 21 opened new positions — a net loss of 22 holders — while 42 trimmed existing stakes and 50 added.
The largest buyer was Deerfield Management, adding an estimated $33.9M. The largest seller was Jennison Associates, cutting an estimated $38.4M.
- 138 institutional investors held Intersect ENT, Inc (XENT) as of Q3 2018, down from 160 in Q2 2018.
- Funds reported $808M of Intersect ENT, Inc stock for Q3 2018, down 22% quarter-over-quarter.
- 21 funds opened new Intersect ENT, Inc positions in Q3 2018 and 43 closed out, a net change of -22 holders.
- The largest Intersect ENT, Inc buyer in Q3 2018 was Deerfield Management, an estimated $33.9M added.
- The largest Intersect ENT, Inc seller in Q3 2018 was Jennison Associates, an estimated $38.4M sold.
Based on aggregated 13F filings for Q3 2018.